KCI expands operations in Brazil

Friday, September 14, 2012 11:44 AM

KCI, a global medical technology company, is expanding existing operations in Brazil.

The expansion will enable KCI to deliver its therapies to more patients and help improve patient outcomes through the provision of specialist wound management training in V.A.C. therapy. It will also contribute to the local economy by creating new jobs.

“Brazil represents a great opportunity for KCI as we look to establish our footprint in South America,” said Jim Cunniff, senior vice president of the Americas, KCI. “With a direct team in Brazil, KCI can offer healthcare professionals specialist skills training in V.A.C. therapy wound management and help treat more patients through our negative pressure wound therapy platform.”

Proprietary KCI negative pressure technologies have changed the way in which caregivers treat a wide variety of wound types. V.A.C. therapy is the only wound care technology substantiated by more than 20 randomized, controlled, clinical trials and over 750 peer-reviewed articles. It has been selected as the treatment of choice for more than 6.5 million wounds worldwide, delivering patient outcomes through well-established mechanisms of action.

“Brazil is at the leading edge of medical technology and many medical advances in Latin America,” said Israel Vierma, vice president of Latin America and Brazil, KCI. “We are excited to broaden our offering of the gold standard of NPWT V.A.C. therapy—so we can help better the lives of more patients.”

KCI has had a presence in Brazil since 2006 through a distributor relationship with EFE Consultoria. KCI will continue to work with EFE and more than a dozen additional distributors in the area to provide KCI NPWT products to multiple call points.

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs